07.10.2019 QIAGEN N.V.  NL0012169213

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019


 

DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results
QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

07-Oct-2019 / 22:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


English Version

Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation

QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019

Venlo, The Netherlands, October 07, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces preliminary sales results for the third quarter of 2019 fall short of expectations.

For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Total sales growth was about 6% CER excluding China sales. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER.

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, regulated market (Prime Standard)

Contacts

John Gilardi

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711 and +1 240 686 2222

[email protected]


07-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: [email protected]
Internet: www.qiagen.com
ISIN: NL0012169213
WKN: A2DKCH
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 886525

 
End of Announcement DGAP News Service

886525  07-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=886525&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 1.172,31 1.269,77 1.183,21 1.311,96 1.362,88 1.527,26 1.817,00
EBITDA1,2 336,02 295,98 308,71 413,21 183,32 482,95 0,00
EBITDA-Marge3 28,66 23,31 26,09 31,50 13,45 31,62 0,00
EBIT1,4 160,79 93,79 128,06 232,88 -23,34 315,55 0,00
EBIT-Marge5 13,72 7,39 10,82 17,75 -1,71 20,66 0,00
Jahresüberschuss1 116,10 76,78 33,72 166,31 -37,01 293,30 0,00
Netto-Marge6 9,90 6,05 2,85 12,68 -2,72 19,20 0,00
Cashflow1,7 290,56 324,18 239,39 314,04 295,40 373,83 0,00
Ergebnis je Aktie8 0,96 0,83 1,06 1,17 -0,16 1,25 1,90
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Qiagen
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2DKCH 46,520 Halten 10.924,48
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
22,15 27,96 0,78 64,17
KBV KCV KUV EV/EBITDA
4,78 29,22 7,15 24,86
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 29.06.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
03.05.2021 12.07.2021 27.10.2020 30.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,66% 8,67% 8,34% 11,11%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu QIAGEN N.V.  ISIN: NL0012169213 können Sie bei DGAP abrufen

Biotechnologie , A2DKCH , QIA , XETR:QIA